S94: H5 Pandemic Influenza Vaccine: Scale-up of transient plant-based expression system

In today's market, process development and scale-up must often be fast-tracked and most importantly must support cGMP manufacture.  Number of doses and quick delivery to market being critical factors in Influenza Vaccine Production, Medicago has developed a high yielding expression system using transient plant-based expression which allows production to start within days after the strain genetic sequence is known.  Medicago is a first responder with speed of production and lost cost of goods. Moreover, simple purification steps have delivered a pure product, meeting the needed Quality, Safety, Efficacy and Stability expected from regulatory agencies which was tested in phase I clinical study.